Obesity reviews : an official journal of the International Association for the Study of ObesityOct 11, 2026

Using Combined Glucagon and Incretin Signals to Treat Obesity and Fatty Liver Disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 12, 2026

Abstract

Glucagon receptor/GLP-1 receptor dual agonists have shown substantial weight loss and improvements in liver health in individuals with obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Glucagon is known for its role in glucose balance but also influences broader metabolic functions, including energy regulation.
Dual agonists targeting both glucagon and GLP-1 receptors may offer benefits by combining the effects of both hormones, with GLP-1 known for reducing hunger.
Animal studies indicate that these dual agonists can lead to reduced food intake, decreased liver fat, and increased energy use.
Early clinical trials have reported significant reductions in body weight, liver fat, and liver scarring with some dual agonists.
The effectiveness of dual agonists compared to GLP-1 mono-agonists remains unclear and requires further head-to-head trials.
The balance of glucagon and GLP-1 signaling in these compounds is crucial for their overall effectiveness and could affect blood sugar control.

Simplified

A resurgence in glucagon research has repositioned this pancreatic hormone as a promising target in the treatment of obesity and related metabolic disorders. Glucagon is classically known for contributing to glucose homeostasis, but emerging evidence points to a much wider role in metabolism, including energy balance and liver health. These findings are fueling attempts to understand how to leverage glucagon signaling to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH). Due to potential hyperglycemic effects of glucagon signaling, most investigational compounds are dual agonists of both the glucagon and glucagon-like peptide-1 (GLP-1) receptors to harness the antihyperglycemic and anorectic effects of the latter hormone, analogs of which such as semaglutide are already proven to be potent obesity medications. Glucagon receptor/GLP-1 receptor dual agonists reduce food intake, decrease hepatic fat, and increase energy expenditure in animal models of obesity and MASH. In early clinical trials, some dual agonists substantially reduced body weight, hepatic steatosis, and hepatic fibrosis. Whether they are more effective than GLP-1 receptor mono-agonists remains to be established in definitive head-to-head studies. The precise balance between glucagon and GLP-1 signaling within individual compounds appears important for overall therapeutic effects-including glycemic control, which worsened with some dual agonists. However, the two most clinically advanced compounds-mazdutide (approved for chronic weight management and type 2 diabetes in China) and survodutide (ongoing global phase 3 trials)-had potent weight-loss and antihyperglycemic effects in people with obesity, with survodutide also improving liver health in people with MASH. Therefore, the research into glucagon physiology that led to glucagon receptor/GLP-1 receptor dual agonists is translating to advantageous new therapies for the highly prevalent diseases of obesity and MASH.

Full Text

Full text is available at the source.

View Full Text ↗

Using Combined Glucagon and Incretin Signals to Treat Obesity and Fatty Liver Disease

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief